Observational, descriptive, retrospective, multicenter study to evaluate the safety of the treatment with Sebryl® and / or Sebryl Plus® in the management of seborrheic dermatitis and psoriasis of the scalp in routine medical practice.
The objective of this study is to evaluate the frequency and intensity of adverse events presented during treatment with Sebryl® and / or Sebryl Plus® for the management of seborrheic dermatitis and psoriasis of the scalp. The sample will be at convenience. The files of the patients who have received treatment with Sebryl® and / or Sebryl Plus® in the last 5 years (2016 to 2021) will be chosen. The researchers or the personnel designated by them will capture the information recorded by the treating physicians in the clinical file, sociodemographic, clinical and safety data that were presented after the prescription of Sebryl® and / or Sebryl Plus®.
Study Type
OBSERVATIONAL
Enrollment
90
Pharmaceutical Form: Shampoo Dosage: Allantoin 0.2 g/ Coal Tar 5.0 g/ Clioquinol 3.0 g Administration way: For scalp use
Pharmaceutical Form: Shampoo Dosage: Allantoin 0.2 g/ Coal Tar 3.0 g/ Clioquinol 3.0 g/ Triclosan 0.3 g. Administration way: For scalp us
Laboratorio Silanes, S.A. de C.V.
Mexico City, Mexico
Proportion of adverse events
Evaluate the presence or absence of adverse events reported in the clinical files.
Time frame: Last 5 years
Classify adverse events
Classify reported adverse events according to seriousness, severity (intensity) and causality of the clinical manifestation
Time frame: Last 5 years
Mean age in years
Describe the mean age in years of the patients included in the study.
Time frame: Last 5 years
Describe study population by gender ratio
Describe the proportion of women and men included in the study
Time frame: Last 5 years
Describe the body mass index through weight and heigh
Describe the body mass index of the study population calculated through weight and heigh of the patient and using the formula kilogram over square meter.
Time frame: Last 5 years
Describe the blood pressure millimetres of mercury (mmHg)
Describe the blood pressure in mmHg of the patients included in the study.
Time frame: Last 5 years
Mean heart rate in beats per minute
Describe the mean heart rate in beats per minute of the patients included in the study.
Time frame: Last 5 years
Percentage of times use outside of expected indications
Percentage of times Sebryl® and / or Sebryl® Plus were used outside of expected indications.
Time frame: Last 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Description of usage pattern according to prescribed dosage
Describe according to prescribed dosage the pattern of use of Sebryl® and / or Sebryl Plus® in the management of seborrheic dermatitis and psoriasis of the scalp.
Time frame: Last 5 years
Description of usage pattern according to prescribed time
Describe according to prescribed time the pattern of use of Sebryl® and / or Sebryl Plus® in the management of seborrheic dermatitis and psoriasis of the scalp.
Time frame: Last 5 years